DALFAMPRIDINE

Post-LOE

Hikma

ANDAORALTABLET, EXTENDED RELEASE

Approved

Oct 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DALFAMPRIDINE by Hikma is elucidated. Approved for walking in adult patients with multiple sclerosis (ms). First approved in 2018.

Drug data last refreshed 22h ago

Mechanism of Action

elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Indications (1)

walking in adult patients with multiple sclerosis (MS)

Clinical Trials (1)

NCT01444300Phase 2Completed

Dalfampridine for Imbalance in Multiple Sclerosis

Started Sep 2011

24 enrolled

Multiple SclerosisFatigue

Company

Worked on DALFAMPRIDINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.